Praxis Precision Medicines Inc. (PRAX)
NASDAQ (NGS) NASDAQ (NGS) Primary Summary
Praxis Precision Medicines, Inc. (PRAX) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Praxis Precision Medicines, Inc. (PRAX) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Praxis' Premium Price May Reflect Unrealistic Market Prospects In Essential Tremor
Praxis Precision Medicines, Inc. is valued as a pure-play on ulixacaltamide's commercial launch in essential tremor, with pipeline optionality limited. I maintain a cautious Hold rating, as PRAX trades above my fair value estimate of $223.73 versus a current share price of $265. Key risks include real-world persistence, payer step edits, and competition from cheap off-label generics, which could materially limit ulixacaltamide's addressable market and duration.
Praxis Precision Medicines, Inc. (PRAX) Presents at Bank of America Global Healthcare Conference 2026 Prepared Remarks Transcript
Praxis Precision Medicines, Inc. (PRAX) Presents at Bank of America Global Healthcare Conference 2026 Prepared Remarks Transcript
Praxis Precision Medicines Inc. Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
| CE Curtis Ellergodt Rothschild Investment LLC | 50 | $3,366.4 | $15,957 | $12,590.6 | 374.01% |
| BG Bart Gancher Intech Investment Management LLC | 6,977 | $635,375.52 | $2.22M | $1.58M | 249.3% |
 John H. Burbank III Passport Capital LLC | 1.75M | $365.47M | $557.69M | $192.22M | 52.59% |
 Didric Cederholm Lion Point Capital LP | 4,450 | $235,850 | $1.42M | $1.18M | 500.18% |
 Joseph Castro Nuveen LLC | 72,043 | $12.04M | $22.87M | $10.83M | 89.96% |
Praxis Precision Medicines Inc. Analysts
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
| JL Joon Lee Truist Securities | -6,376.39 | $401,272.53 | $2.03M | -$1.63M | -405.98% |
Praxis Precision Medicines Inc. (PRAX) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Praxis Precision Medicines Inc. ever had a stock split?
Praxis Precision Medicines Inc. Profile
| Biotechnology Industry | Healthcare Sector | Marcio Silva De'Souza CEO | NASDAQ (NGS) Exchange | 74006W207 CUSIP |
| US Country | 168 Employees | - Last Dividend | 29 Nov 2023 Last Split | 16 Oct 2020 IPO Date |
Overview
Praxis Precision Medicines, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative therapies for central nervous system disorders characterized by an imbalance in neuronal excitation and inhibition. Based in Boston, Massachusetts, and incorporated in 2015, Praxis is committed to addressing the needs of patients with neurological conditions that are often underserved by current treatments. Through its robust pipeline of small molecule and antisense oligonucleotide (ASO) therapies, Praxis aims to target the underlying causes of these disorders. The company's approach involves strategic collaborations and license agreements with industry leaders like RogCon Inc., Ionis Pharmaceuticals, Inc., UCB Biopharma SRL, and The Florey Institute, bolstering its R&D capabilities and expanding its reach in the quest to develop groundbreaking therapies.
Products and Services
- Ulixacaltamide - A small molecule inhibitor of T-type calcium channels, currently in a Phase III clinical trial for treating essential tremor.
- PRAX-562 - Intended for the treatment of pediatric patients with developmental and epileptic encephalopathies (DEE).
- PRAX-628 - A developmental drug aimed at treating focal epilepsy.
- PRAX-222 - Focused on the treatment of pediatric patients with early-onset SCN2A-DEE.
- PRAX-020 - Designed to treat KCNT1 related epilepsies.
- PRAX-080 - For the treatment of PCDH19.
- PRAX-090 and PRAX-100 - Aimed at treating SYNGAP1 and SCN2A-LoF, respectively.
This represents Praxis Precision Medicines, Inc.'s forefront in their development pipeline, aiming to address the significant unmet medical need in the management of essential tremor, a common and debilitating movement disorder.
This innovative therapy is part of Praxis's commitment to combating severe neurological disorders in children, particularly those affected by DEE, a group of rare epilepsy syndromes that cause developmental impairments.
With PRAX-628, Praxis Precision Medicines, Inc. seeks to advance the treatment landscape for patients suffering from focal epilepsy, which accounts for a significant proportion of all epilepsy cases.
Targeting a specific genetic disorder, PRAX-222 exemplifies Praxis's precision medicine approach, aiming at therapies that are genetically and mechanistically tailored to individual conditions.
This program addresses rare, genetic forms of epilepsy associated with the KCNT1 gene, underlining the company's focus on addressing the underlying genetics of epileptic disorders.
By developing PRAX-080, Praxis endeavors to provide targeted therapy for PCDH19, a genetic epilepsy syndrome affecting mainly females, marking a step forward in gender-specific treatment development.
These programs highlight Praxis's ongoing efforts to delve into genetically defined disorders, offering hope for patients with SYNGAP1 and SCN2A loss of function mutations through novel therapeutic approaches.
